🇺🇸 FDA

Company profile · Sponsor

Takeda

Takeda Pharmaceuticals International AG

TAK · NYSE pharma TOKYO, M0, EU
Pipeline
24
Drugs
12
Patents
8

Quick answer

Takeda (TAK) is a pharma company. headquartered in TOKYO, M0, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 12 drugs, and 8 patents to this profile..

Company facts

Ticker TAK
Exchange NYSE
Company type pharma
Headquarters TOKYO, M0, EU
SEC CIK 0001395064

Pipeline (24)

Search pipeline →

  1. 25 mg Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  2. 9vHPV Vaccine

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  3. A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

    Takeda

    Dravet and Lennox-Gastaut Syndromes

    phase 3 other active

    1 trial

  4. ADVATE 500 IU powder and solvent for solution for injection., VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection.

    Takeda

    severe von Willebrand Disease

    phase 3 small molecule active

    1 trial

  5. ALX1-11

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  6. ALX1-11 (drug)

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  7. AMG 479

    Takeda

    Adenocarcinoma of the Pancreas

    phase 3 small molecule completed

    1 trial

  8. AMG 706

    Takeda

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  9. ARALAST NP 60 mg/kg

    Takeda

    Chronic Obstructive Pulmonary Disease

    phase 3 mab terminated

    1 trial

  10. ASCs (Cx401, company code)

    Takeda

    Anal Fistula

    phase 3 small molecule completed

    1 trial

  11. Actovegin

    Takeda

    Post-Stroke Cognitive Impairment (PSCI)

    phase 3 small molecule completed

    1 trial

  12. Actovegin

    Takeda

    Peripheral Arterial Diseases

    phase 3 small molecule completed

    1 trial

  13. Adynovate

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  14. Alisertib

    Takeda

    Relapsed Peripheral T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  15. Alogliptin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    9 trials

  16. Alogliptin Benzoate

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  17. Alogliptin and glimepiride

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  18. Alogliptin and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  19. Alogliptin and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  20. Alogliptin and metformin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  21. Alogliptin and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. Alogliptin and pioglitazone

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  23. Alogliptin and pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  24. Alogliptin and voglibose

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

Drugs (12)

Search drugs →

  1. agalsidase alfa

    REPLAGAL

    A16AB03

  2. alogliptin

    INCRESYNC

    ORAL approved

    A10BD13

  3. alogliptin benzoate

    VIPIDIA

    ORAL approved

    A10BH04

  4. amoxicillin

    AMOXICILLIN AND CLAVULANATE POTASSIUM

    ORAL approved

  5. anagrelide

    ANAGRELIDE VIATRIS (PREVIOUSLY ANAGRELIDE MYLAN)

    L01XX35

  6. anagrelide hydrochloride

    ANAGRELIDE HYDROCHLORIDE

    ORAL approved

  7. apomorphine

    UPRIMA

    G04BE

  8. azilsartan medoxomil

    EDARBI

    approved

    C09CA09

  9. brentuximab vedotin

    ADCETRIS

    INJECTION approved

    L01FX05

  10. brigatinib

    ALUNBRIG

    ORAL approved

    L01XE43

  11. c1 inhibitor (human)

    CINRYZE

    B06AC01

  12. cefotiam hydrochloride

    CERADON

    INJECTION approved

Patents (8)

Search patents →

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12421188

    Heterocyclic compound and use thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12415782

    Heterocyclic compound and use thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12409210

    CNS delivery of therapeutic agents

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Takeda?

Takeda (TAK) is a pharma company. headquartered in TOKYO, M0, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 12 drugs, and 8 patents to this profile..

What pipeline programs does Takeda sponsor?

We track 24 ClinicalTrials.gov-linked programs for Takeda, including 25 mg Ontamalimab and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Takeda company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.